Voyager Therapeutics (NASDAQ:VYGR – Get Free Report)’s stock had its “neutral” rating reissued by Chardan Capital in a note issued to investors on Monday, PriceTargets.com reports. Chardan Capital also issued estimates for Voyager Therapeutics’ FY2024 earnings at ($0.67) EPS.
A number of other research analysts have also weighed in on VYGR. Oppenheimer reaffirmed an “outperform” rating and set a $16.00 price objective on shares of Voyager Therapeutics in a research report on Monday, August 7th. StockNews.com began coverage on Voyager Therapeutics in a research report on Thursday, August 17th. They set a “hold” rating for the company. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.00.
Voyager Therapeutics Stock Down 1.4 %
VYGR opened at $8.04 on Monday. The stock has a market cap of $352.96 million, a PE ratio of 3.54 and a beta of 1.03. The business has a 50 day moving average of $9.21 and a 200-day moving average of $9.60. Voyager Therapeutics has a 52 week low of $4.77 and a 52 week high of $14.34.
Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) last released its earnings results on Thursday, August 3rd. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.08. The firm had revenue of $4.85 million during the quarter, compared to analysts’ expectations of $2.00 million. Equities analysts anticipate that Voyager Therapeutics will post 1.11 EPS for the current year.
Insider Activity at Voyager Therapeutics
In related news, insider Todd Alfred Carter sold 10,500 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $8.16, for a total transaction of $85,680.00. Following the completion of the transaction, the insider now owns 54,360 shares of the company’s stock, valued at approximately $443,577.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.70% of the stock is owned by corporate insiders.
Institutional Trading of Voyager Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the business. California State Teachers Retirement System bought a new stake in shares of Voyager Therapeutics in the 2nd quarter worth $121,000. Nuveen Asset Management LLC bought a new stake in shares of Voyager Therapeutics in the 2nd quarter worth $1,012,000. Alliancebernstein L.P. bought a new stake in shares of Voyager Therapeutics in the 2nd quarter worth $220,000. Wells Fargo & Company MN increased its holdings in shares of Voyager Therapeutics by 624.2% in the 2nd quarter. Wells Fargo & Company MN now owns 14,962 shares of the company’s stock worth $171,000 after purchasing an additional 12,896 shares in the last quarter. Finally, Vestcor Inc bought a new stake in shares of Voyager Therapeutics in the 2nd quarter worth $437,000. Institutional investors own 58.81% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company’s lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer’s disease. It also develops VY-FXN01 to treat Friedreich’s ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson’s disease.